Actinogen (ASX:ACW)
Actinogen Medical is developing a new Alzheimer's drug called Xanamem, which works by targeting excess cortisol. The scientific literature on the Cortisol Hypothesis is encouraging. A Phase 2 trial of Xanamem, entitled XanADu, likely completes in 2019.